Hemophilia – Impact of Recent Advances on Management
- 135 Downloads
There have been numerous advances in the field of hemophilia management in the past decade, including long acting factor products, non-factor products, and potentially curative interventions such as gene therapy. Each of these interventions introduces exciting treatment modalities to patients with both hemophilia A and B, however they also pose a daunting array of possible management options. Adverse reactions to novel agents are being reported as more patients are treated and long-term sustainability of interventions such as gene therapy is yet to be determined. The practicing hematologist should be aware of the intricacies involved in customizing care for their individual patients and be aware of the monitoring strategies for each interventional strategy to avoid adverse events. Upfront cost vs. long term benefit should be considered as choices of treatment strategies are made, especially in resource poor countries. The goal of the newer agents is to decrease annualized bleed rates and avoid debilitating arthropathy. This article looks at current treatment models for prophylaxis and management of inhibitors, reviews the recent advances in the field (with bioengineered factor products, non-factor products and gene therapy) and summarizes the incorporation of these new interventions in the treatment plan for patients with hemophilia.
KeywordsHemophilia Extended half-life products Non-factor replacement products Gene therapy
GP and DN contributed equally to the concept, writing and editing of this review. DN is the guarantor for this paper.
Compliance with Ethical Standards
Conflict of Interest
DN has served as an advisory board member for Bayer, Shire and Novo Nordisk. GP has served as an advisory board member for Octapharma.
- 2.Konkle BA, Huston H, Nakaya FS, Hemophilia A. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle: University of Washington; 1993.Google Scholar
- 7.Collins PW, Blanchette VS, Fischer K, et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413–20.Google Scholar
- 9.Young G. How I treat children with hemophilia and inhibitors. Br J Hematol. 2019;186:400–8.Google Scholar
- 14.Konkle BA, Shapiro A, Quon D, et al. BIVV001: The first investigational factor VIII therapy to break through the VWF ceiling in hemophilia A, with potential for extended protection for one week or longer [Abstract]. Blood. 2018;132:636.Google Scholar
- 16.Powell JS, Pasi KJ, Ragni MC, et al; B-LONG investigators. Phase 3 study of recombinant factor IX fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–23.Google Scholar
- 17.Santagostino E, Martinowitz U, Lissitchkov R, et al; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–9.Google Scholar
- 18.Collins PW, Young G, Knobe, et al; Paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–6.Google Scholar
- 23.Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–53.Google Scholar
- 24.Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors [Abstract]. Blood. 2017;130:85.CrossRefGoogle Scholar
- 28.Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from hemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017;23:769–76.CrossRefPubMedGoogle Scholar
- 36.George LA, Ragni MV, Samelson-Jones BJ, et al. SPK-8011: preliminary results from a phase 1 /2 dose escalation trial of investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.Google Scholar
- 37.Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost. 2019 May 16. https://doi.org/10.1055/s-0039-1688445 [Epub ahead of print].